Giovanni Caforio
Board Chair and CEO at Bristol-Myers Squibb Company
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Bristol-Myers Squibb Company, 3 years.
Bristol-Myers Squibb Company
Director · Executive Chair of the Board
Stryker Corporation
Director
Chief executive roles
Bristol-Myers Squibb Company
· Board Chair and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 6, 2026 | Stryker Corporation | Grant or award | +762 | — | — |
| May 8, 2025 | Stryker Corporation | Grant or award | +560 | — | — |
| May 9, 2024 | Stryker Corporation | Grant or award | +653 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Option exercise | +23,409 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Other | −3,687 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Shares withheld for tax | −10,088 | $53.79 | $542,634 |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Option exercise | +23,817 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Other | −4,104 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Shares withheld for tax | −10,084 | $53.79 | $542,418 |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Option exercise | +142,904 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Other | −49,745 | — | — |
| Mar 10, 2024 | Bristol-Myers Squibb Company | Shares withheld for tax | −47,651 | $53.79 | $2,563,147 |
| Oct 10, 2023 | Bristol-Myers Squibb Company | Gift | −440 | — | — |
| May 10, 2023 | Stryker Corporation | Grant or award | +705 | — | — |
| May 4, 2023 | Stryker Corporation | Option exercise | +841 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.